HOME
>
臨床医学：外科
>
麻酔科学/ペイン
> レミマゾラムQ＆A

レミマゾラムQ＆A

出版社：	克誠堂出版
著者：	稲垣喜三山蔭道明中島芳樹(編)
発行日：	2022-05-01
分野：	臨床医学：外科 > 麻酔科学/ペイン
ISBN：	9784771905627
電子書籍版：	2022-05-01 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：4～8営業日

7,260 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

7,260 円(税込)

購入する

商品紹介

日本で開発された新全身麻酔薬“レミマゾラム”の基本知識からワンランク上の使用法までをQ＆A方式で習得できる。すべての麻酔科医の明日からの臨床麻酔が無限に広がる

目次

第1章　理学的特徴
第2章　麻酔導入
第3章　麻酔維持
第4章　麻酔覚醒
第5章　薬物相互作用
第6章　術後／回復期
第7章　小児麻酔／産科麻酔

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第I章薬理学的特徴

P.5 掲載の参考文献

1) Vuyk J, Sitsen E, Reekers M. Intravenous anesthesia. In : Gropper MA, et al, editors. Miller's anesthesia. Vol 1. 9th ed. Philadelphia : Elsevier ; 2020. p.653.

2) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

3) Kanto JH. Midazolam : the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy 1985 ; 5 : 138-55.

4) アネレム説明文書. 東京 : ムンディファーマ ; 2020.

P.8 掲載の参考文献

1) 薬効薬理. アネレム説明文書. 東京 : ムンディファーマ ; 2020. p.38.

2) Vuyk J, Sitsen E, Reekers M. Intravenous anesthesia. In : Gropper MA, et al, editors. Miller's anesthesia. Vol 1. 9th ed. Philadelphia : Elsevier ; 2020. p.655.

3) Vuyk J, Sitsen E, Reekers M. Intravenous anesthesia. In : Gropper MA, et al, editors. Miller's anesthesia. Vol 1. 9th ed. Philadelphia : Elsevier ; 2020. p.653.

4) 薬物動態. アネレム説明文書. 東京 : ムンディファーマ ; 2020. p.37.

P.11 掲載の参考文献

1) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) Johnson TN, Rostami-Hodjegan A, Goddard JM, et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children : a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002 ; 89 : 428-37 (III).

3) Reves JG, Fragen RJ, Vinik HR, et al. Midazolam : pharmacology and uses. Anesthesiology 1985 ; 62 : 310-24 (III).

4) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

5) 山蔭道明. レミフェンタニルの薬理作用. 日臨麻会誌 2007 ; 27 : 369-80.

6) 今井輝子. カルボキシエステラーゼと創薬. 日本薬理学雑誌 2009 ; 134 : 281-4.

7) Upton RN, Somogyi AA, Martinez AM, et al. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. Br J Anaesth 2010 ; 105 : 798-809.

8) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

9) Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo-and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012 ; 115 : 274-83.

P.16 掲載の参考文献

1) Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part I. Safety, efficacy, and basic pharmacokinetics. Aneth Analg 2012 ; 115 : 274-83.

2) レミマゾラムベシル酸塩アネレム静注用50mg. 第2部 CTDの概要 2.6 非臨床試験の概要文及び概要表 2.6.4 薬物動態試験の概要文. 東京 : ムンディファーマ ; 2018. p.45-51.

3) レミマゾラムベシル酸塩アネレム静注用50mg. 第2部 CTDの概要 2.5 臨床に関する概括評価 2.5.3.2.4.2 肝機能障害者. 東京 : ムンディファーマ ; 2018. p.25.

4) Melendez JA, Stone JG, Delphin E, et al. Influence of temperature on in vitro metabolism of esmolol. J Cardiothorac Anesth 1990 ; 4 : 704-6.

5) Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra-high-performance liquid chromatography coupled with synapt high-definition mass spectrometory. J Pharm Biomed Anal 2017 ; 15 : 78-83.

P.19 掲載の参考文献

1) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) Zhou J, Curd L, Lohmer LL, et al. Population pharmacokinetics of remimazolam in procedural sedation with nonhomogeneously mixed arterial and venous concentrations. Clin Transl Sci 2021 ; 14 : 326-34.

4) Absalom AR, Mani V, De Smet T, et al. Pharmacokinetic models for propofol-defining and illuminating the devil in the detail. Br J Anaesth 2009 ; 103 : 26-37.

5) Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997 ; 86 : 10-23.

P.23 掲載の参考文献

1) Zhou J, Curd L, Lohmer LL, et al. Population pharmacokinetics of remimazolam in procedural sedation with nonhomogeneously mixed arterial and venous concentrations. Clin Transl Sci 2021 ; 14 : 326-34.

P.27 掲載の参考文献

1) https://www.pmda.go.jp/drugs/2020/P20200120002/770098000_30200AMX00031_K100_2.pdf (2020年5月20日閲覧)

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers. Part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) アネレム(R) 静注用50mg 医薬品インタビューフォーム. 東京 : ムンディファーマ. https://mundipharma.co.jp/medical-assets/anerem/anerem-if.pdf

4) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

P.31 掲載の参考文献

1) アネレム(R) 静注用50mg 添付文書. 東京 : ムンディファーマ. https://mundipharma.co.jp/medical-assets/anerem/anerem-pi.pdf

2) アネレム(R) 静注用50mg 医薬品インタビューフォーム. 東京 : ムンディファーマ. https://mundipharma.co.jp/medical-assets/anerem/anerem-if.pdf

3) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

P.36 掲載の参考文献

1) Minto CF, Schnider TW, Gregg KM, et al. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology 2003 ; 99 : 324-33.

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

4) Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992 ; 76 : 334-41.

5) Scott JC, Ponganis KV, Stanski DR. EEG Quantitation of narcotic effect : the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985 ; 62 : 234-41.

6) 増井健一. Context-sensitive half-time (CSHT) とは何を表すものですか? 内田整編. 臨床の疑問に答える静脈麻酔 Q&A 99. 東京 : 羊土社 ; 2015. p.190-1.

P.42 掲載の参考文献

1) 医薬品インタビューフォーム : ドルミカム注射液10mg. 2019年7月 (第2版). (http://image.packageinsert.jp 丸石製薬株式会社 2021年4月15日閲覧)

2) Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender and obesity on midazolam kinetics. Anesthesiology 1984 ; 61 : 27-35.

3) MacGilchrist A, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986 ; 27 : 190-5.

4) Vinik HR, Reves JG, Greenblatt DJ, et al. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 1983 ; 59 : 390-4.

5) Patel IH, Soni PP, Fukuda K, et al. The pharmacokinetics of midazolam in patients with congestive heart failure. Br J Clin Pharmacol 1990 ; 29 : 565-9.

6) 医薬品インタビューフォーム : アネレム静注用50mg. 2020年8 月 (改訂第2版). (http://mundipharma.co.jp 2021年4月12日閲覧)

7) Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012 ; 115 : 284-96.

P.48 掲載の参考文献

1) Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997 ; 85 : 1399-403.

2) Gepts E, Camu F, Cockshott ID, et al. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987 ; 66 : 1256-63.

3) Kirkpatrick T, Cockshott ID, Douglas EJ, et al. Pharmacokinetics of propofol (Diprivan) in elderly patients. Br J Anaesth 1988 ; 60 : 146-50.

4) Servin F, Farinotti R, Haberer J-P, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. Anesthesiology 1993 ; 78 : 657-65.

5) Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990 ; 65 : 177-83.

6) Ickx B, Cockshott ID, Byttebier L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal desease. Br J Anaesth 1998 ; 81 : 854-60.

7) Ghoneim MM, Van Hamme MJ. Pharmacokinetics of thiopentone : effects of enflurane and nitrous oxide anaesthesia and surgery. Br J Anaesth 1978 ; 50 : 1237-42.

8) Vuyk J, Sitsen E, Reekers M. Intravenous anesthetics. In : Gropper MA et al. editors. Miller's Anesthesia. 9th ed. Philadelphia : Churchill Livingstone ; 2020. p.638-79.

第II章麻酔導入

P.56 掲載の参考文献

1) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol 2008 ; 155 : 52-61.

3) Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth 2009 ; 103 : 848-57.

4) Komatsu R, Turan AM, Orhan-Sungur M, et al. Remifentanil for general anaesthesia : a systematic review. Anaesthesia 2007 ; 62 : 1266-80.

5) Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use : a future for subtype-selective GABA (A) receptor modulators? Adv Pharmacol Sci 2012 ; 2012 : 416864.

6) Io T, Saunders R, Pesic M, et al. A miniature pig model of pharmacological tolerance to long-term sedation with the intravenous benzodiazepines ; midazolam and remimazolam. Eur J Pharmacol 2021 ; 896 : 173886.

P.63 掲載の参考文献

1) (株) アールアンドティ. 医療機器・用品年鑑 2020年度版. http://www.rdco.info/237-239.html (2022年2月27日閲覧)

P.66 掲載の参考文献

1) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) Murphy A, Campbell DE, Baines D, et al. Allergic reactions to propofol in egg-allergic children. Anesth Analg 2011 ; 113 : 140-4.

3) Asserhoj LL, Mosbech H, Kroigaard M, et al. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut. Br J Anaesth 2016 ; 116 : 77-82.

4) Anderson BJ, Sinclair J. Food, fads, allergies and anaphylaxis with propofol. Anaesthesia 2019 ; 74 : 1223-6.

5) 梶山誠司, 大澤恭浩, 岡田泰典. プロポフォールの注入時血管痛に対するリドカイン投与法の検討-標的濃度調節持続静注を用いた麻酔導入時について-. 麻酔 2009 ; 58 : 891-6.

P.70 掲載の参考文献

1) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

2) Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999 ; 65 : 630-9.

3) Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999 ; 90 : 1502-16.

4) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

5) Miyake W, Oda Y, Ikeda Y, et al. Electroencephalographic response following midazolam-induced general anesthesia : relationship to plasma and effect-site midazolam concentrations. J Anesth 2010 ; 24 : 386-93.

6) Hamaoka N, Oda Y, Hase I, et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4 : an in vivo and in vitro study. Clin Pharmacol Ther 1999 ; 66 : 110-7.

7) Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012 ; 115 : 274-83.

8) Zhou J, Leonowens C, Ivaturi VD, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth 2020 ; 66 : 109899.

9) Kanazawa S, Oda Y, Maeda C, et al. Age-dependent decrease in desflurane concentration for maintaining bispectral index below 50. Acta Anaesthesiol Scand 2016 ; 60 : 177-82.

10) Matsuura T, Oda Y, Tanaka K, et al. Advance of age decreases the minimum alveolar concentrations of isoflurane and sevoflurane for maintaining bispectral index below 50. Br J Anaesth 2009 ; 102 : 331-5.

11) Yasuda N, Lockhart SH, Eger EI 2nd, et al. Comparison of kinetics of sevoflurane and isoflurane in humans. Anesth Analg 1991 ; 72 : 316-24.

P.75 掲載の参考文献

1) Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation scale : study with intravenous midazolam. J Clin Psychopharmacol 1990 ; 10 : 244-51.

2) Schuller PJ, Newell S, Strickland PA, et al. Response of bispectral index to neuromuscular block in awake volunteers. Br J Anaesth 2015 ; 115 : i95-i103.

3) Sigel E, Margot E. Benzodiazepine binding site of GABAA receptors. Trends Pharmacol Sci 2018 ; 39 : 659-71.

P.78 掲載の参考文献

1) Zacny JP, Coalson D, Young C, et al. A dose-response study of the effects of intravenous midazolam on cold pressor-induced pain. Anesth Analg 1995 ; 80 : 521-5.

2) Goodchild C, Noble J. The effects of intrathecal midazolam on sympathetic nervous system reflexes in man-a pilot study. Br J Clin Pharmacol 1987 ; 23 : 279-85.

3) Cox RF, Collins MA. The effects of benzodiazepines on human opioid receptor binding and function. Anesth Analg 2001 ; 93 : 354-8.

4) Rosland JH, Hole K. Benzodiazepine-induced antagonism of opioid antinociception may be abolished by spinalization or blockade of the benzodiazepine receptor. Pharmacol Biochem Behav 1990 ; 37 : 505-9.

5) Gear RW, Miaskowski C, Heller PH, et al. Benzodiazepine mediated antagonism of opioid analgesia. Pain 1997 ; 71 : 25-9.

6) Guignard B, Bossard Anne E, Coste C, et al. Acute opioid tolerance : intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000 ; 93 : 409-17.

7) Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth Analg 1998 ; 86 : 1307-11.

8) Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005 ; 103 : 147-55.

P.83 掲載の参考文献

1) Hino H, Matsuura T, Kihara Y, et al. Comparison between hemodynamic effects of propofol and thiopental during general anesthesia induction with remifentanil infusion : a double-blind, age-stratified, randomized study. J Anesth 2019 ; 33 : 509-15.

2) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

3) Masui K, Kira M, Kazama T, et al. Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate. Anesthesiology 2009 ; 111 : 805-17.

4) Zhou J, Leonowens C, Ivaturi VD, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth 2020 ; 66 : 109899.

5) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

6) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

P.87 掲載の参考文献

1) Egan T. Is anesthesiology going soft? Anesthesiology 2009 ; 111 : 229-30.

2) Gavin J, Margaret S, Richard F, et al. CNS 7056 A novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

3) Alexandra M, Michael P, Raymond J, et al. Remimazolam : pharmacologic considerations and clinical role in anesthesiology. Pharmacotherapy 2016 ; 36 : 1021-7.

4) Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999 ; 39 : 1109-25.

5) Kanto JH. Midazolam : The first water-soluble benzodiazepine : pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy 1985 ; 5 : 138-55.

6) Freyer N, Knoespel F, Damm G, et al. Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system. Drug Des Dev Ther 2019 ; 13 : 1033-47.

7) Li Di. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab 2019 ; 20 : 91-102.

8) Human Protein Atlas. https://www.proteinatlas.org/search/CES (Accessed March 14, 2021)

9) レミマゾラムべシル酸塩 2.5 臨床に関する概括評価. https://www.pmda.go.jp/drugs/2020/P20200120002/770098000_30200AMX00031_G100_1.pdf (Accessed January 20, 2021)

10) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA class3) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

11) Xiao-yan S, Yan L, Xue-yuan Y, et al. Safety, pharmacokinetic and pharmacodynamic proper ties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol 2020 ; 76 : 383-91.

12) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

13) Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth 1990 ; 65 : 177-83.

14) Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anesthesia in patients with end-stage renal disease. Br J Anaesth 1998 ; 81 : 854-60.

15) 藤野裕士. 集中治療における鎮静. 日集中医誌 2006 ; 13 : 21-6.

16) Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984 ; 61 : 27-35.

P.91 掲載の参考文献

1) Lemmens H, Bernstein DP, Brodsky J. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006 ; 16 : 773-6.

2) Goudra B, Mason KP. Emerging approaches in intravenous moderate and deep sedation. J Clin Med 2021 ; 10 : 1735-41.

3) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

4) Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure : dosing guidelines for adults and children. 5th ed. Philadelphia : American College of Physicians ; 2007.

5) 日本肥満学会. 肥満症診療ガイドライン 2016. 東京 : ライフサイエンス出版 ; 2016.

6) Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010 ; 105 Suppl 1 : i16-23.

第III章麻酔維持

P.97 掲載の参考文献

1) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) Kilpatrick GJ, Mclntyre MS, Cox RF, et al. CNS 7056. Anesthesiology 2007 ; 107 : 60-6.

3) ムンディファーマ株式会社. インタビューフォームアネレム(R) 静注用 50mg. 2020年8月改定.

4) Whilyshire H, Kilpatrick G, Tilbrook G, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012 ; 115 : 284-96.

5) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers. Anesthesiology 2020 ; 132 : 636-51.

6) Lohmer L, Schippers F, Petersen KU, et al. Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia. J Clin Pharmacol 2020 ; 60 : 505-14.

7) Worthington MT, Antonik LJ, Goldwater DR, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. Anesth Analg 2013 ; 117 : 1093-100.

8) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

9) Morimoto Y. Usefulness of electroencephalogramic monitoring during general anesthesia. J Anesth 2008 ; 22 : 498-501.

10) Zhou J, Leonowens C, Ivaturi V, et al. Pupulation pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subject. J Clin Anesth 2020 ; 66 : 109899.

P.102 掲載の参考文献

1) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

2) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

3) Stept WJ, Safar P. Rapid induction-intubation for prevention of gastric-content aspiration. Anesth Analg 1970 ; 49 : 633-6.

4) 浅井隆. これでわかった! 図説ラリンジアルマスク. 東京 : 克誠堂出版 ; 2009.

5) Drage MP, Nunez J, Vaughan RS, et al. Jaw thrusting as a clinical test to assess the adequate depth of anaesthesia for insertion of the laryngeal mask. Anaesthesia 1996 ; 51 : 1167-70.

6) Asai T, Vaughan RS. Misuse of the laryngeal mask. Anaesthesia 1994 ; 49 : 467-9.

7) Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012 ; 115 : 274-83.

8) Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012 ; 115 : 284-96.

9) Pastis NJ, Yarmus LB, Schippers F, et al. Safety and Efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 2019 ; 155 : 137-46.

P.107 掲載の参考文献

1) Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol 2020 ; 33 : 506-11.

2) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

3) Ibrahim AE, Taraday JK, Kharasch ED. Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol. Anesthesiology 2001 ; 95 : 1151-9.

4) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

5) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patient (ASA Class III) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

6) Wesselink EM, Kappen TH, Torn HM, et al. Intraoperative hypotension and the risk of postoperative adverse outcomes : a systematic review. Br J Anaesth 2018 ; 121 : 706-21.

7) Steinmetz J, Christensen KB, Lund T, et al. Long-term consequences of postoperative cognitive dysfunction. Anesthesiology 2009 ; 110 : 548-55.

8) Hughes CG, Boncyk CS, Culley DJ, et al. ; Perioperative Quality Initiative (POQI) 6 Workgroup. American society for enhanced recovery and perioperative quality initiative joint consensus statement on postoperative delirium prevention. Anesth Analg 2020 ; 130 : 1572-90.

P.111 掲載の参考文献

1) Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol 2020 ; 33 : 506-11.

2) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

3) 米国医薬品評価研究センター報告 (2020年) : BYFAVO (remimazolam). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000ClinPharmR.pdf (2021年5月1日閲覧)

4) Boulieu R, Lehmann B, Salord F, et al. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998 ; 23 : 255-8.

P.116 掲載の参考文献

1) Ruetzler K, Khanna AK, Sessler DI. Myocardial injury after noncardiac surgery : preoperative, intraoperative, and postoperative aspects, implications, and directions. Anesth Analg 2020 ; 131 : 173-86.

2) Puelacher C, Lurati Buse G, Seeberger D, et al. Peioperative myocardial injury after noncardiac surgery : incidence, mortality, and characterization. Circulation 2018 ; 137 : 1221-32.

3) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

4) Saito K, Ohno S, Maeda M, et al. Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass : a case report. JA Clin Rep 2021 ; 7 : 21.

5) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

6) Shekar K, Roberts JA, Mcdonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 2012 ; 16 : R194.

7) Liu Y, Chen K, Mei W. Neurological complications after cardiac surgery : anesthetic considerations based on outcome evidence. Curr Opin Anaesthesiol 2019 ; 32 : 563-7.

P.121 掲載の参考文献

1) Merton PA, Morton HB. Stimulation of the cerebral cortex in the intact human subject. Nature 1980 ; 285 : 227.

2) Kalkman CJ, Drummond JC, Ribberink AA, et al. Effects of propofol, etomidate, midazolam, and fentanyl on motor evoked responses to transcranial electrical or magnetic stimulation in humans. Anesthesiology 1992 ; 76 : 502-9.

3) Kondo T, Toyota Y, Narasaki S, et al. Intraoperative responses of motor evoked potentials to the novel intravenous anesthetics remimazolam during spine surgery : a report of two cases. JA Clin Rep 2020 ; 9 : 97.

4) Schonle PW, Isenberg C, Crozier TA, et al. Changes of transcranially evoked motor responses in man by midazolam, a short acting benzodiazepine. Neurosci Lett 1989 ; 101 : 321-4.

5) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiaze pine. Anesthesiology 2007 ; 107 : 60-6.

6) Kakinohana M, Nakamura S, Fuchigami T, et al. Influence of the descending thoracic aortic cross clamping on bispectral on bispectral index value and plasma propofol concentration in humans. Anesthesiology 2006 ; 104 : 939-43.

P.127 掲載の参考文献

1) Kanaya A, Kuratani N, Satoh D, et al. Lower incidence of emergence agitation in children after propofol anesthesia compared with sevoflurane : a meta-analysis of randomized controlled trials. J Anesth 2014 ; 28 : 4-11.

2) Kumar G, Stendall C, Mistry R, et al. A comparison of total intravenous anaesthesia using propofol with sevoflurane or desflurane in ambulatory surgery : systematic review and meta-analysis. Anaesthesia 2014 ; 69 : 1138-50.

3) Sato T, Kato Y, Yamamoto M, et al. Novel anesthetic agent remimazolam as an alternative for the asleep-awake-asleep technique of awake craniotomy. JA Clin Rep 2020 ; 6 : 92.

4) Yoshida A, Kurata S, Kida K, et al. Anesthetic management for the sleep-awake-sleep technique of awake craniotomy using a novel benzodiazepine remimazolam and its antagonist flumazenil. JA Clin Rep 2021 ; 7 : 14.

5) Kondo T, Toyota Y, Narasaki S, et al. Intraoperative responses of motor evoked potentials to the novel intravenous anesthetic remimazolam during spine surgery : a report of two cases. JA Clin Rep 2020 ; 6 : 97.

6) Kayama T, Guidelines committee of the Japan awake surgery conference. The guidelines for awake craniotomy guidelines committee of the Japan awake surgery conference. Neurol Med Chir (Tokyo) 2012 ; 52 : 119-41.

7) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

8) Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991 ; 42 : 1061-89.

P.134 掲載の参考文献

1) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) Schuttler J, Eisenries A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers. Part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 ; 636-51.

3) Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth published online.

4) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

5) Eisenries A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 ; 652-66.

P.139 掲載の参考文献

1) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

2) Polc P, Bonetti EP, Schaffner R, et al. A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol 1982 ; 321 : 260-4.

3) Olsen RW. GABAA receptor : positive and negative allosteric modulators. Neuropharmacology 2018 ; 136 : 10-22. PMID : 29407219.

4) McAdam LC, MacDonald JF, Orser BA. Isobolographic analysis of the interactions between midazolam and propofol at GABA (A) receptors in embryonic mouse neurons. Anesthesiology 1998 ; 89 : 1444-54.

5) Hong DM, Kim CS, Eom W, et al. Interactions of midazolam and propofol on α1β2γ2L and α1β2γ2S gamma aminobutyric acid type A receptors expressed in human embryonic kidney cells. Anesth Analg 2011 ; 112 : 1096-102.

6) Sebel LE, Richardson JE, Singh SP, et al. Additive effects of sevoflurane and propofol on gamma-aminobutyric acid receptor function. Anesthesiology 2006 ; 104 : 1176-83.

7) レミマゾラムベシル酸塩. アネレム静注用50mg. 2.7.2 臨床薬理の概要. ムンディファーマ社資料.

8) Short TG, Chui PT. Propofol and midazolam act synergistically in combination. Br J Anaesth 1991 ; 67 : 539-45.

9) McClune S, McKay AC, Wright PM, et al. Synergistic interaction between midazolam and propofol. Br J Anaesth 1992 ; 69 : 240-5.

10) Vinik HR, Bradley EL Jr, Kissin I. Triple anesthetic combination : propofol-midazolam-alfentanil. Anesth Analg 1994 ; 78 : 354-82.

11) Sahinovic MM, Struys MMRF, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet 2018 ; 57 : 1539-58.

12) Diz JC, Del Rio R, Lamas A, et al. Analysis of pharmacodynamic interaction of sevoflurane and propofol on Bispectral Index during general anaesthesia using a response surface model. Br J Anaesth 2010 ; 104 : 733-9.

13) Harris RS, Lazar O, Sebel PS, et al. Interaction of propofol and sevoflurane on loss of consciousness and movement to skin incision during general anesthesia. Anesthesiology 2006 ; 104 : 1170-5.

14) Schumacher PM, Dossche J, Mortier EP, et al. Response surface modeling of the interaction between propofol and sevoflurane. Anesthesiology 2009 ; 111 : 790-804.

15) van den Berg JP, Vereecke HEM, Proost JH, et al. Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. Br J Anaesth 2017 ; 118 : 44-57.

16) Miyake W, Oda Y, Ikeda Y, et al. Effect of remifentanil on cardiovascular and bispectral index responses following the induction of anesthesia with midazolam and subsequent tracheal intubation. J Anesth 2010 ; 24 : 161-7.

17) Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol 2008 ; 155 : 52-61.

18) Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth 2009 ; 103 : 848-57.

19) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

20) Miyake W, Oda Y, Ikeda Y, et al. Electroencephalographic response following midazolam-induced general anesthesia : relationship to plasma and effect-site midazolam concentrations. J Anesth 2010 ; 24 : 386-93.

21) Gugino LD, Chabot RJ, Prichep LS, et al. Quantitative EEG changes associated with loss and return of consciousness in healthy adult volunteers anaesthetized with propofol or sevoflurane. Br J Anaesth 2001 ; 87 : 421-8.

22) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

23) Robinson BJ, Ebert TJ, O'Brien TJ, et al. Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? Anesthesiology 1997 ; 86 : 64-72.

P.144 掲載の参考文献

1) 全身麻酔剤アネレム静注用50mg. 注射用レミマゾラムべシル酸塩. 医薬品インタビューフォーム. 東京 : ムンディファーマ ; 2020.

2) Sasaki H, Hoshijima H, Mizuta K. Ringer's acetate solution-induced precipitation of remimazolam. Br J Anaesth 2021 ; 126 : e87-9.

第IV章麻酔覚醒

P.150 掲載の参考文献

1) Plaud B, Debaene B, Donati F, et al. Residual paralysis after emergence from anesthesia. Anesthesiology 2010 ; 112 : 1013-22.

2) Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer's Assessment of Alertness/Sedation scale : study with intravenous midazolam. J Clin Psychopharmacol 1990 ; 10 : 244-51.

3) ムンディファーマ. レミマゾラム国内一般臨床試験 (ONO-2745-06 試験) 承認時評価資料.

4) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

5) Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth 1995 ; 7 : 89-91.

P.156 掲載の参考文献

1) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

P.165 掲載の参考文献

1) 治験薬ONO-2745 レミマゾラムべシル酸塩 : 医薬品申請前相談取りまとめ書. 株式会社PAION UK, 株式会社Integrated Development Associate.

2) Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the observer's assessment of alertness/sedation scale : study with intravenous midazolam. J Clin Psychopharmacol 1990 ; 10 : 244-51.

3) Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012 ; 115 : 284-96.

4) Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910 ; 40 : 4-7.

5) Schwilden H, Schuttler J, Stoekel H. Pharmacokinetics as applied to total intravenous anaesthesia : theoretical considerations. Anaesthesia 1983 ; 83 : 51-2.

6) Ibrahim AE, Taraday JK, Kharasch ED. Bispectral index monitoring during sedation with sevoflurane, midazolam, and propofol. Anesthesiology 2001 ; 95 : 1151-9.

7) Smith WD, Dutton RC, Smith NT. Measuring the performance of anesthetic depth indicators. Anesthesiology 1996 ; 84 : 38-51.

8) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

9) Rampil IJ. A primer for EEG signal processing in anesthesia. Anesthesiology 1998 ; 89 : 980-1002.

P.169 掲載の参考文献

1) Eisenried A, Schuttler J, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology 2020 ; 132 : 652-66.

2) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

3) Lohmer L, Schippers F, Petersen KU, et al. Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia. J Clin Pharmacol 2020 ; 60 : 505-14.

P.174 掲載の参考文献

1) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

2) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

3) 新宮興, 大澤正巳, 森健次郎. ICI35868 (プロポフォール) 第I相試験. 麻酔 1990 ; 39 : 219-29.

4) Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology 1997 ; 86 : 24-33.

P.179 掲載の参考文献

1) Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc 2018 ; 88 : 427-37.

2) Pastis NJ, Yarmus LB, Schippers F, et al. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest 2019 ; 155 : 137-46.

3) 桂川孝行, 土井松幸. 2 レミマゾラム. 新山幸俊編. 日めくり麻酔科エビデンスアップデート～ 1日1つ, 3カ月で100の知見を得る～. 東京 : 克誠堂出版 ; 2020. p.20-1.

P.183 掲載の参考文献

1) Webster LR, Karan S. The physiology and maintenance of respiration : a narrative review. Pain Ther 2020 ; 9 : 467-86.

2) Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. Br J Anaesth 2009 ; 103 : 848-57.

3) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

P.188 掲載の参考文献

1) Braestrup C, Schmiechen R, Neef G, et al. Interaction of convulsive ligands with benzodiazepine receptors. Science 1982 ; 216 : 1241-3.

2) 関野久之, 中道昇, 神村秀隆ほか. YM 684 (Flumazenil) の臨床第1相試験. 医学と薬学 1990 ; 23 : 777-96.

3) 全身麻酔剤アネレム(R) 静注用 : 注射用レミマゾラムベシル酸塩インタビューフォーム. 東京 : ムンディファーマ ; 2020.

4) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

5) 水野樹. 拮抗作用から見た麻酔関連薬物の最新知見フルマゼニル. 麻酔 2013 ; 62 : 10-8.

6) Spivey WH. Flumazenil and seizures : analysis of 43 cases. Clin Ther 1992 ; 14 : 292-305.

7) 瀧治夫, 篠村徹太郎, 白神豪太郎. フルマゼニルにより痙攣発作が誘発された1症例. 麻酔 1996 ; 45 : 1247-51.

8) Ujike Y, Yamamoto S, Nishikawa K, et al. Flumazenil-induced convulsion after a week sedation by ketamine and midazolam infusion in a postoperative patient. 麻酔と蘇生 1994 ; 30 : 67-8.

P.192 掲載の参考文献

1) 医薬品インタビューフォーム. アネキセート注射液0.5mg. 東京 : アステラス製薬 ; 2019.

2) Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth 2021 ; 35 : 222.

3) 医薬品インタビューフォーム. アネレム静注用50mg. 東京 : ムンディファーマ ; 2020.

4) Jensen S, Knudsen L, Kirkegaard L, et al. Flumazenil used for antagonizing the central effects of midazolam and diazepam in outpatients. Acta Anaesthesiol Scand 1989 ; 33 : 26-8.

5) Mathus-Vliegen EMH, deJong L, Kos-Foekema A. Significant and safe shortening of the recovery time after flumazenil-reversed midazolam sedation. Dig Dis Sci 2014 ; 59 : 1717-25.

6) Shoar NS, Bistas KG, Saadababi A. Flumazemil. Statpearls. 2020. https://www.ncbi.nlm.nih.gov/books/NBK470180/

P.196 掲載の参考文献

1) 医薬品インタビューフォーム. アネキセート注射液0.5mg. 東京 : アステラス製薬 ; 2019年1月改訂.

2) 医薬品インタビューフォーム. アネレム静注用50mg. 東京 : ムンディファーマ ; 2020年8月改訂.

3) Berg KA, Clerke WP. Making sense of pharmacology : inverse agonism and functional selectivity. Int J Neuropsychopharmacol 2018 ; 21 : 962-77

4) Noblet J. Pharmacodynamics and receptor physiology. Update in Anaesthesia. 2008. http://www.worldanaesthesia.org

5) Hauser CAE, Wetzel CHR, Berning B, et al. Flunitrazepam has an inverse agonistic effect on recombinant alpha6beta2 gamma2-GABAA receptors via a flunitrazepam-binding site. J Biol Chem 1997 ; 272 : 11723-7.

P.200 掲載の参考文献

1) Lepouse C, Lautner CA, Liu L, et al. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth 2006 ; 96 : 747-53.

2) Yu D, Chai W, Sun X, et al. Emergence agitation in adults : risk factors in 2,000 patients. Can J Anaesth 2010 ; 57 : 843-8.

3) Wiinholdt D, Eriksen SAN, Harms LB, et al. Inadequate emergence after non-cardiac surgery-A prospective observational study in 1000 patients. Acta Anaesthesiol Scand 2019 ; 63 : 1137-42.

4) Fields A, Huang J, Schroeder D, et al. Agitation in adults in the post-anaesthesia care unit after general anaesthesia. Br J Anaesth 2018 ; 121 : 1052-8.

5) Wei B, Feng Y, Chen W, et al. Risk factors for emergence agitation in adults after general anesthesia : a systematic review and meta-analysis. Acta Anaesthesiol Scand 2020 doi : 10.1111/aas.13774.

6) Card E, Pandharipande P, Tomes C, et al. Emergence from general anaesthesia and evolution of delirium signs in the post-anaesthesia care unit. Br J Anaesth 2015 ; 115 : 411-7.

7) Costi D, Cyna AM, Ahmed S, et al. Effects of sevoflurane versus other general anaesthesia on emergence agitation in children. Cochrane Database Syst Rev 2014 : CD007084 doi : 10.1002/14651858.CD007084.pub2

8) Cho E-A, Cha Y-B, Shim J-G, et al. Comparison of single minimum dose administration of dexmedetomidine and midazolam for prevention of emergence delirium in children : a randomized controlled trial. J Anesth 2020 ; 34 : 59-65.

9) Chandler JR, Myers D, Mehta D, et al. Emergence delirium in children : a randomized trial to compare total intravenous anesthesia with propofol and remifentanil to inhalational sevoflurane anesthesia. Paediatr Anaesth 2013 ; 23 : 309-15.

10) Jo J-Y, Jung K-W, Kim H-J, et al. Effect of total intravenous anesthesia vs volatile induction with maintenance anesthesia on emergence agitation after nasal surgery : a randomized clinical trial. JAMA Otolaryngol Neck Surg 2019 ; 145 : 117-23.

11) Remimazolam reduces emergence delirium in preschool children undergoing laparoscopic surgery by sevoflurane anesthesia : a double-blinded randomized clinical trial. clinicaltrials. https://clinicaltrials.gov/ct2/show/NCT04621305

P.204 掲載の参考文献

1) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) Upton RN, Somogyi AA, Martinez AM, et al. Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. Br J Anaesth 2010 ; 105 : 798-809.

4) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

5) Doi M, Hirata N, Suzuki T, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III) : results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth 2020 ; 34 : 491-501.

6) Amrein R, Hetzel W, Hartmann D, et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol 1988 ; Suppl 2 : 65-80.

P.209 掲載の参考文献

1) von Ungern-Sternberg BS, Boca K, Chambers NA, et al. Risk assessment for respiratory complications in paediatric anaesthesia : a prospective cohort study. Lancet 2010 ; 376 : 773-83.

2) Moore AD, Anghelescu DL. Emergence delirium in pediatric anesthesia. Pediatr Drugs 2017 ; 19 : 11-20.

3) Rogers WK, Mcdowell TS. Remimazolam, a short-acting GABA (A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010 ; 13 : 929-37.

4) Kilpatric GJ, Mclntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

5) von Ungern-Sterberg BS, Erb PO, Frei FJ. Management of upper airway in spontaneously breathing children. A challenge of the anaesthetist. Anaesthetist 2006 ; 55 : 164-70.

6) Ruiqiang S, Guolin W, Xuesong G, et al. Flumazenil reduces respiratory complications during anesthesia emergence in children with preoperative upper respiratory tract infections. Medicine (Baltimore) 2018 ; 97 : 17 (e0516). doi : 10.1097/MD.0000000000010516.

7) Bhananker SM, Ramamoorthy C, Geiduschek JM, et al. Anesthesia-related cardiac arrest in children : up-date from the pediatric perioperative cardiac arrest registry. Anesth Analg 2007 ; 105 : 344-50.

8) Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. Anesth Analg 2004 ; 99 : 1648-54.

9) Sun L, Guo R, Sun L. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children : a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2014 ; 58 : 642-50.

10) Mari K, Shinji K, Takuro S, et al. The effect of midazolam administration for the prevention of emergence agitation in pediatric patients with extreme fear and non-cooperation undergoing dental treatment under sevoflurane anesthesia, a double-blind, randomized study. Drug Des Devel Ther 2019 ; 13 : 1729-37.

11) Kim MS, Moon BE, Kim H, et al. Comparison of propofol and fentanyl administered at the end of anaesthesia for prevention of emergence agitation after sevoflurane anaesthesia in children. Br J Anaesth 2013 ; 110 : 274-80.

P.214 掲載の参考文献

1) Peterson GN, Domino KB, Caplan RA, et al. Management of the difficult airway : a closed claims analysis. Anesthesiology 2005 ; 103 : 33-9.

2) Popat M, Mitchell V, Dravid R, et al. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012 ; 67 : 318-40.

3) Liu F-L, Cherng Y-G, Chen S-Y, et al. Postoperative recovery after anesthesia in morbidly obese patients : a systematic review and meta-analysis of randomized controlled trials. Can J Anesth 2015 ; 62 : 907-17.

4) Leeson S, Roberson RS, Philip JH. Hypoventilation after inhaled anesthesia results in reanesthetization. Anesth Analg 2014 ; 119 : 829-35.

P.219 掲載の参考文献

1) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) 国内後期第II相/第III相臨床試験 (ONO-2745-05 試験)

4) 国内第I相臨床試験 (ONO-2745-02 試験)

第V章薬物相互作用

P.229 掲載の参考文献

1) Kurita T, Uraoka M, Jiang Q, et al. Influence of cardiac output on the pseudo-steady state remifentanil and propofol concentrations in swine. Acta Anaesthesiol Scand 2013 ; 57 : 754-60.

2) Platten HP, Schweizer E, Dilger K, et al. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 1998 ; 63 : 552-60.

3) Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology 1997 ; 86 : 24-33.

4) Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997 ; 86 : 10-23.

5) Zhou J, Leonowens C, Ivaturi VD, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth 2020 ; 66 : 109899.

6) Lohmer LL, Schippers F, Petersen KU, et al. Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia. J Clin Pharmacol 2020 ; 60 : 505-14.

7) Minto CF, Schnider TW, Short TG, et al. Response surface model for anesthetic drug interactions. Anesthesiology 2000 ; 92 : 1603-16.

8) Vinik HR, Bradley EL Jr, Kissin I. Midazolam-alfentanil synergism for anesthetic induction in patients. Anesth Analg 1989 ; 69 : 213-7.

P.233 掲載の参考文献

1) Zhou J, Leonowens C, Ivaturi VD, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth 2020 ; 66 : 109899.

2) Varrique RM, Lauretti GR, Matsumoto JA, et al. Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. J Pharm Pharmacol 2016 ; 68 : 1351-8.

3) Olkkola KT, Tammisto T. Quantifying the interaction of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and isoflurane using closed-loop feedback control of rocuronium infusion. Anesth Analg 1994 ; 78 : 691-6.

4) Kuipers JA, Boer F, Olofsen E, et al. Recirculatory pharmacokinetics and pharmacodynamics of rocuronium in patients : the influence of cardiac output. Anesthesiology 2001 ; 94 : 47-55.

5) Farkas S, Tarnawa I, Berzsenyi P. Effects of some centrally acting muscle relaxants on spinal root potentials : a comparative study. Neuropharmacology 1989 ; 28 : 161-73.

6) Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage 1994 ; 9 : 434-41.

7) Montravers P, Dureuil B, Desmonts JM. Effects of i.v. midazolam on upper airway resistance. Br J Anaesth 1992 ; 68 : 27-31.

8) Leiter JC, Knuth SL, Bartlett D Jr. The effect of sleep deprivation on activity of the genioglossus muscle. Am Rev Respir Dis 1985 ; 132 : 1242-5.

9) Dhonneur G, Combes X, Leroux B, et al. Postoperative obstructive apnea. Anesth Analg 1999 ; 89 : 762-7.

10) Lee CH, Hong SL, Rhee CS, et al. Analysis of upper airway obstruction by sleep videofluoroscopy in obstructive sleep apnea : a large population-based study. Laryngoscope 2012 ; 122 : 237-41.

11) Agro F, Salvinelli F, Casale M, et al. Difficulty in airway management during sedation of patients affected by obstructive sleep apnea. Can J Anaesth 2004 ; 51 : 279.

12) Koo SK, Choi JW, Myung NS, et al. Analysis of obstruction site in obstructive sleep apnea syndrome patients by drug induced sleep endoscopy. Am J Otolaryngol 2013 ; 34 : 626-30.

13) Abdullah VJ, Lee DL, Ha SC, et al. Sleep endoscopy with midazolam : sedation level evaluation with bispectral analysis. Otolaryngol Head Neck Surg 2013 ; 148 : 331-7.

P.238 掲載の参考文献

1) Brosen K. lsozyme specific drug oxidation : genetic polymorphism and drug-drug interactions. Nord J Psychiatry 2009 ; 47 : 21-6.

2) Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007 ; 32 : 333-41.

3) 佐藤重一. 不眠症治療薬剤と他剤との相互作用. 薬局 1995 ; 46 : 65-71.

4) Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056 : a novel ultra-short-acting benzodiazepine. Anesthesiology 2007 ; 107 : 60-6.

5) Stohr T, Colin PJ, Ossig J, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth 2021 ; 127 : 415-23.

6) Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol 2020 ; 33 : 506-11.

7) 今井浩光, 大橋京一. 薬力学からみた薬物相互作用. ICUとCCU 2008 ; 32 : 1089-97.

8) Sands BF, Greelman WL, Ciaulo DA, et al. Benzodiazepines. In : Ciaulo DA, Shader RL, Greenblatt DJ, et al. edtors. Drug Interactions in Psychiatry. Baltimore : Williams and Wilkins ; 1995. p.214-48.

9) Fiset P, Lemmens HL, Egan TD, et al. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin Pharmacol Ther 1995 ; 58 : 567-82.

10) Worthington MT, Antonik LJ, Goldwater DR, et al. A phase I b, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg 2013 ; 117 : 1093-100.

11) 山元健太朗, 河野敬明, 稲田健. ベンゾジアゼピン系やバルビツール系などの治療薬依存. 日本臨牀 2019 ; 77 : 425-30.

12) Yoshikawa H, Hosokawa M, Kashima Y, et al. Remimazolam tolerance in long-term benzodiazepine users : a case report of 2 cases. A A Pract 2021 ; 15 (5) : e01460.

第VI章術後 / 回復期

P.243 掲載の参考文献

1) Salmasi V, Masheshwari K, Yang D, et al. Relationship between intraoperative hypotension, defined by either reduction from baseline or absolute thresholds, and acute kidney and myocardial injury after noncardiac surgery : a retrospective cohort analysis. Anesthesiology 2017 ; 126 : 47-65.

2) Walsh M, Devereaux PJ, Garg AX, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery. Anesthesiology 2013 ; 119 : 507-15.

3) Turan A, Rivas E, Devereaux PJ, et al. Association between postoperative haemoglobin concentrations and composite of non fatal myocardial infarction and all-cause mortality in noncardiac surgical patients : post hoc analysis of POISE-2 trial. Br J Anaesth 2021 ; 126 : 87-93.

4) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

5) 平田直之, 柴田賢吾, 大中崇行ほか. レミマゾラム : 薬理学的特徴と臨床での使用法. 臨床麻酔 2021 ; 45 : 9-15.

P.248 掲載の参考文献

1) Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013 ; 41 : 263-306.

2) Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018 ; 46 : e825-73.

3) Van Rompaey B, Elseviers MM, Schuurmans MJ, et al. Risk factors for delirium in intensive care patients : a prospective cohort study. Crit Care 2009 ; 13 (3) : R77.

4) Fraser GL, Devlin JW, Worby CP, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults : a systematic review and meta-analysis of randomized trials. Crit Care Med 2013 ; 41 (9 Suppl 1) : S30-8.

5) Chen TJ, Chung YW, Chang HCR, et al. Diagnostic accuracy of the CAM-ICU and ICDSC in detecting intensive care unit delirium : a bivariate meta-analysis. Int J Nurs Stud 2021 ; 113 : 103782.

6) Kassie GM, Nguyen TA, Kalisch Ellett LM, et al. Preoperative medication use and postoperative delirium : a systematic review. BMC Geriatr 2017 ; 17 : 298.

7) Lu Y, Li Y-W, Wang L, et al. Promoting sleep and circadian health may prevent postoperative delirium : a systematic review and meta-analysis of randomized clinical trials. Sleep Med Rev 2019 ; 48 : 101207.

8) Saczynski JS, Marcantonio ER, Quach L, et al. Cognitive trajectories after postoperative delirium. N Engl J Med 2012 ; 367 : 30-9.

9) Patel SB, Poston JT, Pohlman A, et al. Rapidly reversible, sedation-related delirium versus persistent delirium in the intensive care unit. Am J Respir Crit Care Med 2014 ; 189 : 658-65.

P.253 掲載の参考文献

1) Siddiqui N, Arzola C, Teresi J, et al. Predictors of desaturation in the postoperative anesthesia care unit : an observational study. J Clin Anesth 2013 ; 25 : 612-7.

2) Gali B, Whalen FX, Schroeder DR, et al. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and postanesthesia care assessment. Anesthesiology 2009 ; 110 : 869-77.

3) Kaw R, Chung F, Pasupuleti V, et al. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br J Anaesth 2012 ; 109 : 897-906.

4) Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. Minerva Anestesiol 2016 ; 82 : 735-42.

5) Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry : an international prospective, observational trial. Anesth Analg 2020 ; 131 : 1012-24.

6) Upton R, Martinez A, Grant C. A dose escalation study in sheep of the effects of the benzodiazepine CNS 7056 on sedation, the EEG and the respiratory and cardiovascular systems. Br J Pharmacol 2008 ; 155 : 52-61.

7) Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy : a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res 2020 ; 12 : 4594-603.

8) 医薬品インタビューフォーム. 全身麻酔剤アネレム(R) 静注用50mg. 東京 : ムンディファーマ ; 2020年8月改定.

9) Sessler DI, Meyhoff CS, Zimmerman NM, et al. Period-dependent associations between hypotension during and for four days after noncardiac surgery and a composite of myocardial infarction and death : a substudy of the POISE-2 trial. Anesthesiology 2018 ; 128 : 317-27.

10) Smischney NJ, Shaw AD, Stapelfeldt WH, et al. Postoperative hypotension in patients discharged to the intensive care unit after non-cardiac surgery is associated with adverse clinical outcomes. Crit Care 2020 ; 24 : 682.

11) van Lier F, Wesdorp FHIM, Liem VGB, et al. Association between postoperative mean arterial blood pressure and myocardial injury after noncardiac surgery. Br J Anaesth 2018 ; 120 : 77-83.

12) Miller TE, Mythen M, Shaw AD, et al. Association between perioperative fluid management and patient outcomes : a multicentre retrospective study. Br J Anaesth 2021 ; 126 : 720-9.

P.258 掲載の参考文献

1) Wiltshire HR, Kilpatric GJ, Tilbrook GS, et al. Placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056) : part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg 2012 ; 115 : 284-96.

2) Schuttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers : part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology 2020 ; 132 : 636-51.

3) Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia : a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020 ; 34 : 543-53.

4) Gupta A, Stierer T, Zuckerman R, et al. Comparison of recovery profile after ambulatory anesthesia with propofol, sevoflurane, and desflurane : a systematic review. Anesth Analg 2004 ; 98 : 632-41.

5) Song D, Joshi GP, White PF, et al. Fast-track eligibility after ambulatory anesthesia : a comparison of desflurane, sevoflurane, and propofol. Anesth Analg 1998 ; 86 : 267-73.

6) Amrein R, Hetzel W, Hartmann D, et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol 1988 ; 2 Suppl : 65-80.

7) Hughes MA, Glass PSA, Jacobs JR, et al. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992 ; 76 : 334-41.

8) White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg 2002 ; 94 : 577-85.

9) Ong CK, Seymour RA, Lirk P, et al. Combining paracetamol (acetaminophen) with nonsteroidal anti-inflammatory drugs : a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010 ; 110 : 1170-9.

10) Maeda A, Katafuchi T, Oba Y, et al. Enhancement of GABAergic tonic currents by midazolam and noradrenaline in rat substantia gelatinosa neurons in vitro. Anesthesiology 2010 ; 113 : 429-37.

P.265 掲載の参考文献

1) Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004 ; 350 : 2441-51.

2) Tong JG. Postoperative nausea and vomiting-can it be eliminated? JAMA 2002 ; 287 : 1233-6.

3) Tong JG, Pierre D, Ashraf SH, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014 ; 118 : 85-113.

4) Mehernoor FW, Paul FW. Postoperative nausea and vomiting its etiology, treatment, and prevention. Anesthesiology 1992 ; 77 : 162-84.

5) Chandrakantan A, Glass PSA. Multimodal therapies for postoperative nausea and vomiting, and pain. Br J Anaesth 2011 ; 107 Suppl 1 : i27-40.

6) Gan TJ, Glass PS, Howell ST, et al. Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. Anesthesiolgy 1997 ; 87 : 779-84.

7) Kevin P, Patrick M, Antonio M, et al. Preoperative intravenous midazolam : benefits beyond anxiolysis. J Clin Anesth 2004 ; 16 : 177-83.

8) William M, Helen B, Eugene A, et al. Midazolam reduces vomiting after tonsillectomy in children. Can J Anaesth 1995 ; 42 : 201-3.

9) Lee Y, Wang JJ, Yang YL, et al. Midazolam vs ondansetron for preventing postoperative nausea and vomiting : a randomized controlled trial. Anaesthesia 2007 ; 62 : 18-22.

10) Sherif AA, Mohamed SK. A prospective controlled study to assess the antiemetic effect of midazolam following intragastric balloon insertion. J Anaesthesiol Clin Pharmacol 2014 ; 30 : 383-6.

11) Michel C, Jimin K, Andrew J, et al. The effect of intravenous midazolam on postoperative nausea and vomiting : a meta-analysis. Aneth Analg 2016 ; 122 : 656-63.

12) Florio TD. The use of midazolam for persistent postoperative nausea and vomiting. Anaesth Intensive Care 1992 ; 20 : 383-6.

13) Habib AS. Midazolam-an anti-emetic? Anaesthesia 2002 ; 57 : 725.

P.271 掲載の参考文献

1) 長田理. III 周術期の合併症管理 3 神経・筋系 7) 術中覚醒. 水本一弘編. 麻酔科プラクティス 5. 麻酔科必携周術期のリスク管理～安全対策・感染予防・合併症管理. 東京 : 文光堂 ; 2021. p.221-6.

2) 長田理, 加藤孝子, 服部貢士ほか. 薬物動態シミュレーションを用いたレミマゾラム意識消失時効果部位濃度と維持投与速度の検討. 麻酔 2021 ; 70 Suppl : 160 (PW29-08).

3) Miyanishi M, Yaguramaki T, Maehara Y, et al. Three cases of difficulty in achieving definitive loss of consciousness with remimazolam. JA Clin Rep 8, Article number : 4 (2022). https://doi.org/10.1186/s40981-021-00485-1.

P.275 掲載の参考文献

1) Popat M, Mitchell V, Dravid R, et al. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012 ; 67 : 318-40.

2) 高橋正裕, 中橋一喜, 辛嶋百合ほか. 全身麻酔覚醒時の抜管記憶に関する検討. 麻酔 2001 ; 50 : 613-8.

3) Inoue S, Abe R, Tanaka Y, et al. Anesthesia management by residents does not alter the incidence of recall of tracheal extubation : a teaching hospital-based propensity score analysis. Rev Bras Anestesiol 2017 ; 67 : 251-7.

4) Sandin RH, Enlund G, Samuelsson P, et al. Awareness during anaesthesia : a prospective case study. Lancet 2000 ; 355 : 707-11.

5) Pandit JJ, Andrade J, Bogod DG, et al. 5 th National Audit Project (NAP5) on accidental awareness during general anaesthesia : summary of main findings and risk factors. Br J Anaesth 2014 ; 113 : 549-59.

P.280 掲載の参考文献

1) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 137 : 860-6.

2) 河野崇. 術後神経認知障害-脳内炎症を標的とした予防・治療戦略-. 日集中医誌 2018 ; 25 : 12-9.

3) 合谷木徹. 術後せん妄と術後認知機能障害. 麻酔 2015 ; 64 増刊 : S41-50.

4) Li W-X, Luo R-Y, Chen C, et al. Effects of propofol, dexmedetomidine, and midazolam on postoperative cognitive dysfunction in elderly patients : a randomized controlled preliminary trial. Chin Med J 2019 ; 132 : 437-45.

5) 祖父江和哉. 基礎研究から見る麻酔薬の認知機能への影響. 医学のあゆみ 2020 ; 272 : 649-51.

6) La Monaca E, Fodale V. Effects of anesthetics on mitochondrial signaling and function. Curr Drug Saf 2012 ; 7 : 126-39.

7) Yamamoto T, Kurabe M, Kamiya Y. Re-sleeping after reversal of remimazolam by flumazenil. J Anesth 2021 ; 35 : 322.

8) Fritz BA, Kalarickal PL, Maybrier HR. Intraoperative electroencephalogram suppression predicts postoperative delirium. Anesth Analg 2016 ; 122 : 234-42.

9) 河野崇. 術後神経・認知機能異常の新たな展開. Cardiovasc Anesth 2020 ; 24 : 27-33.

10) Kondo T, Toyota Y, Narasaki S, et al. Intraoperative responses of motor evoked potentials to the novel intravenous anesthetic remimazolam during spine surgery : a report of two cases. JA Clin Rep 2020 ; 6 : 97.

P.285 掲載の参考文献

1) Bailey CR, Ahuja M, Bartholomew K, et al. Guidelines for day-case surgery 2019 : Guidelines from the Association of Anaesthetists and the British Association of Day Surgery. Anaesthesia 2019 ; 74 : 778-92.

第VII章小児麻酔 / 産科麻酔

P.293 掲載の参考文献

1) 土井松幸. レミマゾラム. 日臨麻会誌 2014 ; 34 : 860-6.

P.297 掲載の参考文献

1) アネレム静注用50mg薬剤添付文書. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/770098_1119403F1024_1_01 (2021.6 閲覧)

2) レミマゾラムベシル酸塩薬物動態試験の概要文. https://www.pmda.go.jp/drugs/2020/P20200120002/770098000_30200AMX00031_I100_1.pdf (2021.6 閲覧)

3) Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft : meta-analysis of cohort and case-control studies. BMJ 1998 ; 317 : 839-43.

4) Bellantuono C, Tofani S, Di Sciascio G, et al. Benzodiazepine exposure in pregnancy and risk of major malformations : a critical overview. Gen Hosp Psychiatry 2013 ; 35 : 3-8.

5) Sprung J, Flick RP, Katusic SK, et al. Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia. Mayo Clin Proc 2012 ; 87 : 120-9.

6) Glatz P, Sandin RH, Pedersen NL, et al. Association of anesthesia and surgery during childhood with long-term academic performance. JAMA Pediatr 2017 ; 171 : e163470.

7) Warner DO, Zaccariello MJ, Katusic SK, et al. Neuropsychological and behavioral outcomes after exposure of young children to procedures requiring general anesthesia : the Mayo anesthesia safety in kids (MASK) study. Anesthesiology 2018 ; 129 : 89-105.

8) McCann ME, de Graaff JC, Dorris L, et al. Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS) : an international, multicentre, randomised, controlled equivalence trial. Lancet 2019 ; 393 : 664-77. Erratum in : Lancet 2019 Aug 24 ; 394 (10199) : 638.

9) Davidson AJ, Disma N, de Graaff JC, et al. Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS) : an international multicentre, randomised controlled trial. Lancet 2016 ; 387 : 239-50.

10) Sun LS, Li G, Miller TL, et al. Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. JAMA 2016 ; 315 : 2312-20.

11) McDonnell NJ, Paech MJ, Clavisi OM, et al. Difficult and failed intubation in obstetric anaesthesia : an observational study of airway management and complications associated with general anaesthesia for caesarean section. Int J Obstet Anesth 2008 ; 17 : 292-7.

12) Pandit JJ, Andrade J, Bogod DG, et al. Royal College of Anaesthetists ; Association of anaesthetists of Great Britain and Ireland. 5 th national audit project (NAP5) on accidental awareness during general anaesthesia : summary of main findings and risk factors. Br J Anaesth 2014 ; 113 : 549-59.

書評

書評を投稿する

最近チェックした商品履歴

Loading...